IL17A and myeloid sarcoma: Fluoxetine has been found to reduce IL-17, IFN-γ, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-21 production by CD4+ T-cells stimulated with anti-CD3/CD28-microbeads in patients with relapsing–remitting MS and healthy subjects without affecting immune cell viability and proliferative response.